Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4459387
Max Phase: Preclinical
Molecular Formula: C17H19ClN6O2
Molecular Weight: 374.83
Molecule Type: Unknown
Associated Items:
ID: ALA4459387
Max Phase: Preclinical
Molecular Formula: C17H19ClN6O2
Molecular Weight: 374.83
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCNCCn1cc(-c2ccc(Cl)c(NC(=O)c3coc(N)n3)c2)cn1
Standard InChI: InChI=1S/C17H19ClN6O2/c1-2-20-5-6-24-9-12(8-21-24)11-3-4-13(18)14(7-11)22-16(25)15-10-26-17(19)23-15/h3-4,7-10,20H,2,5-6H2,1H3,(H2,19,23)(H,22,25)
Standard InChI Key: RDJAJMYWFQKNLB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 374.83 | Molecular Weight (Monoisotopic): 374.1258 | AlogP: 2.64 | #Rotatable Bonds: 7 |
Polar Surface Area: 111.00 | Molecular Species: BASE | HBA: 7 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.93 | CX Basic pKa: 9.82 | CX LogP: 1.92 | CX LogD: -0.44 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.55 | Np Likeness Score: -2.02 |
1. (2018) Oxazole derivatives for use in the treatment of cancer, |
Source(1):